Fundraising FoxAcre Venture Partners — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Infinant Health develops probiotic products based on B. infantis strains that work with breast milk to support the infant gut microbiome, including its INF108 drug strain aimed at preventing necrotizing enterocolitis (NEC) in premature infants.
BiotechDigital HealthFemTechHealthtechMedical DevicesWellness & FitnessSacramento, US
David J. Kyle(Executive Officer, Director)inJ. Bruce German(Co-founder)David Mills(Founder)inCarlito Lebrilla(Founder)Daniela Barile(Founder)Samara Freeman(Founder & Executive Director, Regulatory Affairs & Intellectual Property)in
Co-investorsBow CapitalHorizons VenturesiSelect FundLongitude CapitalSpruce Capital PartnersXeraya Capital+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.